Pascal Biosciences



Pascal Biosciences Year-End Investor Update Webcast: Advancement of Cannabinoid Cancer Programs and Corporate Review

December 17, 2018 at 1:30 PM PT

To access the archived webcast, please log on at the link below:

Webcast Link


Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones MORE >

Pascal Biosciences Announces Year-End Investor Update Webcast - Monday, December 17th at 1:30PM PST MORE >

Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs MORE >

CFN Media's Exclusive Interview with Pascal Biosciences MORE >

Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells MORE >

Pascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer MORE >

Pascal Biosciences appoints Julie M. Eastland, accomplished financial executive, to Board of Directors MORE >

Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration MORE >

Pascal Biosciences Identifies Molecules in Cannabis That Stimulate the Immune System to Destroy Tumor Cells MORE >

Pascal Announces the Appointment of a New Director, Dr. Graeme I. Bell MORE >